EA201992802A1 - Биофармацевтические композиции и связанные с ними способы - Google Patents
Биофармацевтические композиции и связанные с ними способыInfo
- Publication number
- EA201992802A1 EA201992802A1 EA201992802A EA201992802A EA201992802A1 EA 201992802 A1 EA201992802 A1 EA 201992802A1 EA 201992802 A EA201992802 A EA 201992802A EA 201992802 A EA201992802 A EA 201992802A EA 201992802 A1 EA201992802 A1 EA 201992802A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- asthma
- eosinophilic
- moderate
- severe
- atopic dermatitis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229960000074 biopharmaceutical Drugs 0.000 title 1
- 208000006673 asthma Diseases 0.000 abstract 10
- 102000000743 Interleukin-5 Human genes 0.000 abstract 4
- 108010002616 Interleukin-5 Proteins 0.000 abstract 4
- 229940100602 interleukin-5 Drugs 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 206010034277 Pemphigoid Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000000594 bullous pemphigoid Diseases 0.000 abstract 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037851 severe atopic dermatitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к антигенсвязывающим композициям, включая антитела, для лечения заболеваний, опосредованных интерлейкином 5 (IL-5), и к связанным с ними способам. IL-5 является секретируемым белком и играет роль в ряде различных заболеваний, таких как астма, легкая астма, астма средней тяжести, тяжелая астма, легкая эозинофильная астма, эозинофильная астма средней тяжести, тяжелая эозинофильная астма, неконтролируемая эозинофильная астма, эозинофильная астма, суб-эозинофильная астма, хроническая обструктивная болезнь легких, эозинофильный гранулематоз с полиангиитом, гиперэозинофильный синдром, носовые полипы, буллезный пемфигоид, эозинофильный эзофагит, атопический дерматит, атопический дерматит средней тяжести и тяжелый атопический дерматит. Раскрытые композиции пригодны для лечения этих серьезных заболеваний, опосредованных IL-5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511441P | 2017-05-26 | 2017-05-26 | |
| PCT/IB2018/053683 WO2018215964A1 (en) | 2017-05-26 | 2018-05-24 | Biopharmaceutical compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992802A1 true EA201992802A1 (ru) | 2020-07-10 |
Family
ID=62683386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992802A EA201992802A1 (ru) | 2017-05-26 | 2018-05-24 | Биофармацевтические композиции и связанные с ними способы |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10787509B2 (ru) |
| EP (1) | EP3630824A1 (ru) |
| JP (2) | JP7224304B2 (ru) |
| KR (1) | KR102473898B1 (ru) |
| CN (5) | CN117018189A (ru) |
| AR (1) | AR111764A1 (ru) |
| AU (2) | AU2018273174B2 (ru) |
| BR (1) | BR112019024884A2 (ru) |
| CA (1) | CA3064522A1 (ru) |
| CL (1) | CL2019003418A1 (ru) |
| CO (1) | CO2019013245A2 (ru) |
| CR (1) | CR20190541A (ru) |
| DO (1) | DOP2019000297A (ru) |
| EA (1) | EA201992802A1 (ru) |
| IL (1) | IL270719A (ru) |
| MX (1) | MX2019014105A (ru) |
| MY (1) | MY200912A (ru) |
| NZ (1) | NZ760380A (ru) |
| PE (1) | PE20191844A1 (ru) |
| PH (1) | PH12019502619A1 (ru) |
| SG (1) | SG10201913497XA (ru) |
| TW (1) | TWI799417B (ru) |
| UY (1) | UY37747A (ru) |
| WO (1) | WO2018215964A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI799417B (zh) | 2017-05-26 | 2023-04-21 | 英商葛蘭素史克智慧財產發展有限公司 | 生物製藥組成物及相關方法 |
| WO2019224724A1 (en) * | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions comprising antibody variants |
| US20220010008A1 (en) * | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
| WO2022136209A1 (en) | 2020-12-22 | 2022-06-30 | Glaxosmithkline Intellectual Property Development Limited | Interleukin 5 binding protein dosage regimen |
| WO2023099668A1 (en) | 2021-12-03 | 2023-06-08 | Glaxosmithkline Intellectual Property Development Limited | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL194312B1 (pl) | 1994-12-23 | 2007-05-31 | Smithkline Beecham Corp | Przeciwciało monoklonalne neutralizujące gryzoni,linia hybrydoma, humanizowane przeciwciało, region CDR ciężkiego łańcucha immunoglobuliny, region CDR lekkiego łańcucha immunoglobuliny, cząsteczki kwasu nukleinowego, przeciwciało chimeryczne, kompozycja farmaceutyczna, izolowana sekwencja kwasu nukleinowego, rekombinowany plazmid i komórka gospodarza oraz sposób wytwarzania humanizowanego przeciwciała i sposób wspomagania diagnostyki alergii |
| US5683892A (en) | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| AU2008201419C1 (en) * | 2000-12-12 | 2018-01-18 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| EP2152310A4 (en) | 2007-04-30 | 2010-05-26 | Glaxosmithkline Llc | METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES |
| BRPI0910854A2 (pt) | 2008-03-28 | 2015-10-06 | Glaxosmithkline Llc | métodos de tratamento |
| US9334331B2 (en) * | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
| WO2012083370A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MA42692A (fr) | 2015-08-24 | 2018-07-04 | Glaxosmithkline Ip No 2 Ltd | Compositions biopharmaceutiques |
| PE20191662A1 (es) | 2016-12-23 | 2019-11-11 | Cephalon Inc | Anticuerpos anti-il-5 |
| TWI799417B (zh) | 2017-05-26 | 2023-04-21 | 英商葛蘭素史克智慧財產發展有限公司 | 生物製藥組成物及相關方法 |
| WO2019224724A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions comprising antibody variants |
-
2018
- 2018-05-24 TW TW107117675A patent/TWI799417B/zh active
- 2018-05-24 PE PE2019002461A patent/PE20191844A1/es unknown
- 2018-05-24 EP EP18732488.4A patent/EP3630824A1/en active Pending
- 2018-05-24 WO PCT/IB2018/053683 patent/WO2018215964A1/en active Application Filing
- 2018-05-24 UY UY0001037747A patent/UY37747A/es unknown
- 2018-05-24 EA EA201992802A patent/EA201992802A1/ru unknown
- 2018-05-24 AR ARP180101401A patent/AR111764A1/es unknown
- 2018-05-24 CN CN202311013609.8A patent/CN117018189A/zh active Pending
- 2018-05-24 KR KR1020197037587A patent/KR102473898B1/ko active IP Right Grant
- 2018-05-24 US US15/987,942 patent/US10787509B2/en active Active
- 2018-05-24 NZ NZ760380A patent/NZ760380A/en unknown
- 2018-05-24 BR BR112019024884-6A patent/BR112019024884A2/pt unknown
- 2018-05-24 MX MX2019014105A patent/MX2019014105A/es unknown
- 2018-05-24 MY MYPI2019006883A patent/MY200912A/en unknown
- 2018-05-24 CN CN202311013236.4A patent/CN117018188A/zh active Pending
- 2018-05-24 JP JP2019565279A patent/JP7224304B2/ja active Active
- 2018-05-24 AU AU2018273174A patent/AU2018273174B2/en active Active
- 2018-05-24 CN CN202311013988.0A patent/CN117018190A/zh active Pending
- 2018-05-24 CA CA3064522A patent/CA3064522A1/en active Pending
- 2018-05-24 CN CN202311014554.2A patent/CN117100853A/zh active Pending
- 2018-05-24 CN CN201880046323.0A patent/CN110891968B/zh active Active
- 2018-05-24 SG SG10201913497XA patent/SG10201913497XA/en unknown
- 2018-05-24 CR CR20190541A patent/CR20190541A/es unknown
-
2019
- 2019-11-17 IL IL270719A patent/IL270719A/en unknown
- 2019-11-21 PH PH12019502619A patent/PH12019502619A1/en unknown
- 2019-11-22 CL CL2019003418A patent/CL2019003418A1/es unknown
- 2019-11-22 DO DO2019000297A patent/DOP2019000297A/es unknown
- 2019-11-26 CO CONC2019/0013245A patent/CO2019013245A2/es unknown
-
2020
- 2020-08-07 US US16/988,257 patent/US11976113B2/en active Active
-
2021
- 2021-09-17 AU AU2021232807A patent/AU2021232807A1/en active Pending
-
2023
- 2023-01-31 JP JP2023013628A patent/JP2023058546A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992802A1 (ru) | Биофармацевтические композиции и связанные с ними способы | |
| CL2018000499A1 (es) | Composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados. | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| NO20082767L (no) | Kimaere og humaniserte anti-humane IL-13 antistoffer | |
| EA201291147A1 (ru) | Анти-c5a-антитела и способы применения антител | |
| EA201791137A1 (ru) | Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
| TN2017000541A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| EA201591462A1 (ru) | Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений | |
| EA201790476A1 (ru) | Аминопиридилоксипиразольные соединения | |
| WO2015073580A8 (en) | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof | |
| WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
| EA202092094A1 (ru) | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 | |
| EA201291273A1 (ru) | Ингибиторы киназ, регулирующих апоптозный сигнал | |
| NO20070189L (no) | Immunoglobuliner | |
| EA201891143A1 (ru) | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 | |
| BR112015023086A2 (pt) | anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença. | |
| WO2015127140A3 (en) | Marburg monoclonal antibodies | |
| JP2018537399A5 (ru) | ||
| EA202190807A1 (ru) | Антитела к синуклеину | |
| MX2021014164A (es) | Moleculas de union a cd19 y usos de las mismas. | |
| BR112016023980A2 (pt) | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) | |
| MX2021015553A (es) | Inhibidores de arginasa novedosos. |